Abstract: Inhibitor of apoptosis protein-like protein-2 (ILP-2) has only been detected in the testis and in lymphoblastoid cells. Although previous studies have not reported the presence of ILP-2 in breast cancer tissues, this study indicates the presence of ILP-2 in breast cancer serum samples. To validate whether ILP-2 is a novel serological biomarker for breast cancer, we conducted two-dimensional gel electrophoresis (2DE) and matrix-assisted laser desorption/ionization-time of flight mass spectrometry analysis on 400 breast cancer serum samples and 40 non-cancer serum samples (i.e., healthy controls). We then performed a Western blot analysis of 10 breast cancer serum samples and 10 non-cancer serum samples. Finally, we analyzed 35 serum samples from healthy controls or subjects with breast cancer, other types of cancer, galactophore hyperplasia or breast cancer post-surgery by using 2DE and enzyme-linked immunosorbent assay. Our results indicate that ILP-2 is a novel breast cancer biomarker in the peripheral blood.
Keywords: ILP-2; breast cancer; serological biomarker
Export to BibTeX
MDPI and ACS Style
Xiang, M.; Zhou, W.; Gao, D.; Fang, X.; Liu, Q. Inhibitor of Apoptosis Protein-Like Protein-2 as a Novel Serological Biomarker for Breast Cancer. Int. J. Mol. Sci. 2012, 13, 16737-16750.
Xiang M, Zhou W, Gao D, Fang X, Liu Q. Inhibitor of Apoptosis Protein-Like Protein-2 as a Novel Serological Biomarker for Breast Cancer. International Journal of Molecular Sciences. 2012; 13(12):16737-16750.
Xiang, Mingjun; Zhou, Wei; Gao, Dandan; Fang, Xiansong; Liu, Qian. 2012. "Inhibitor of Apoptosis Protein-Like Protein-2 as a Novel Serological Biomarker for Breast Cancer." Int. J. Mol. Sci. 13, no. 12: 16737-16750.